Firth Christine, Harris Lucinda A, Smith Maxwell L, Thomas Leslie F
Department of Internal Medicine, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Division of Gastroenterology, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Case Rep Nephrol Dial. 2018 Nov 27;8(3):261-267. doi: 10.1159/000494714. eCollection 2018 Sep-Dec.
Cronkhite-Canada syndrome (CCS) is a very rare disorder with less than 500 reported cases. It is characterized by extensive gastrointestinal polyposis and ectodermal anomalies including alopecia, cutaneous hyperpigmentation, and onychodystrophy. Only 3 cases of associated kidney disease (membranous nephropathy [MN]) have been reported. A 71-year-old male with CCS was referred for further evaluation of proteinuria. The patient initially presented with abdominal discomfort, weight loss, dysgeusia, skin hyperpigmentation, alopecia, and dystrophic nails. Endoscopic evaluation showed widespread gastrointestinal nodular inflammation and polyps. Histopathology was consistent with CCS. Initial treatment was with prednisone, azathioprine, and ranitidine. He had moderate clinical improvement but developed nephrotic-range proteinuria. Renal biopsy showed MN, and cyclosporine was started. The patient had significant improvement in his CCS manifestations; however, his proteinuria and renal function worsened. Rituximab was added to his regimen of cyclosporine and azathioprine, which resulted in remission of his MN, marked improvement in his polyposis, and near resolution of his cutaneous symptoms. This case represents a unique presentation of CCS associated with MN treated with rituximab. The excellent clinical response observed for both CCS and MN advocates consideration of this treatment, especially for refractory disease.
克朗凯特-加拿大综合征(CCS)是一种非常罕见的疾病,报告病例少于500例。其特征为广泛的胃肠道息肉病和外胚层异常,包括脱发、皮肤色素沉着和甲营养不良。仅报告了3例相关肾病(膜性肾病[MN])。一名71岁患有CCS的男性因蛋白尿进一步评估而就诊。患者最初表现为腹部不适、体重减轻、味觉障碍、皮肤色素沉着、脱发和指甲营养不良。内镜评估显示广泛的胃肠道结节性炎症和息肉。组织病理学与CCS一致。初始治疗采用泼尼松、硫唑嘌呤和雷尼替丁。他有中度临床改善,但出现了肾病范围的蛋白尿。肾活检显示为MN,开始使用环孢素。患者的CCS表现有显著改善;然而,他的蛋白尿和肾功能恶化。利妥昔单抗被添加到他的环孢素和硫唑嘌呤治疗方案中,这导致他的MN缓解,息肉病明显改善,皮肤症状几乎消退。该病例代表了用利妥昔单抗治疗的与MN相关的CCS的独特表现。观察到的CCS和MN的良好临床反应提倡考虑这种治疗方法,特别是对于难治性疾病。